MX2019010573A - Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. - Google Patents

Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno.

Info

Publication number
MX2019010573A
MX2019010573A MX2019010573A MX2019010573A MX2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A MX 2019010573 A MX2019010573 A MX 2019010573A
Authority
MX
Mexico
Prior art keywords
montelukast
receptor antagonists
leukotriene receptor
treatment
improved bioavailability
Prior art date
Application number
MX2019010573A
Other languages
English (en)
Spanish (es)
Inventor
G Zerbe Horst
Paiement Nadine
Obeid Rodolphe
W Conway Justin
Original Assignee
Intelgenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelgenx Corp filed Critical Intelgenx Corp
Publication of MX2019010573A publication Critical patent/MX2019010573A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019010573A 2017-03-30 2018-03-29 Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno. MX2019010573A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478876P 2017-03-30 2017-03-30
PCT/CA2018/050389 WO2018176149A1 (en) 2017-03-30 2018-03-29 Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists

Publications (1)

Publication Number Publication Date
MX2019010573A true MX2019010573A (es) 2019-10-24

Family

ID=63673863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010573A MX2019010573A (es) 2017-03-30 2018-03-29 Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno.

Country Status (9)

Country Link
EP (1) EP3600265A1 (de)
JP (1) JP2020512309A (de)
KR (1) KR20190128637A (de)
CN (1) CN110381931A (de)
AU (1) AU2018241534A1 (de)
BR (1) BR112019018388A2 (de)
CA (1) CA3056944A1 (de)
MX (1) MX2019010573A (de)
WO (1) WO2018176149A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150213A1 (en) * 2018-09-14 2022-03-19 Intelgenx Corp. TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST
US20210393611A1 (en) * 2018-11-05 2021-12-23 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US11602504B2 (en) * 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物
CN114931578A (zh) * 2022-05-16 2022-08-23 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 孟鲁司特在制备用于治疗***性红斑狼疮药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
KR101077468B1 (ko) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
EA038558B1 (ru) * 2013-10-14 2021-09-14 Зим Лэбораториз Лимитед Водорастворимая фармацевтическая пленка с повышенной стабильностью
US9668970B2 (en) * 2013-12-02 2017-06-06 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
CN104784157B (zh) * 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂

Also Published As

Publication number Publication date
JP2020512309A (ja) 2020-04-23
AU2018241534A1 (en) 2019-09-26
CA3056944A1 (en) 2018-10-04
KR20190128637A (ko) 2019-11-18
EP3600265A1 (de) 2020-02-05
CN110381931A (zh) 2019-10-25
BR112019018388A2 (pt) 2020-04-07
WO2018176149A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
MX2019010573A (es) Metodo de tratamiento y dispositivo para la biodisponibilidad mejorada de antagonistas receptores de leucotrieno.
MX2019004096A (es) Dispositivo y metodo para tratar condiciones asociadas con neuroinflamacion.
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
WO2015123576A3 (en) Targeted nanoparticle compositions and methods of their use to treat obesity
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HRP20211046T1 (hr) Upotreba derivata benzimidazola kod noćnog proboja kiseline
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
SI2413933T1 (en) 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
PH12016500063A1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3150213A1 (en) TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
EA201890575A1 (ru) Композиции и способы сенсибилизации паразитов к лекарственным средствам
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2016193456A3 (en) Opioid receptor antagonist for use in treating patients with severe constipation
CY1120693T1 (el) Συνδυασμος ενος αναστολεα κινασης ρι3 με πακλιταξελη για χρηση στη θεραπεια ή προληψη ενος καρκινου κεφαλης και τραχηλου
EA201491046A1 (ru) Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
BR0313423A (pt) Medicamento para o tratamento contra a ânsia por uma substância devido a uma dependência
WO2018231176A3 (en) COMBINATIONS OF DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION
EA201991384A1 (ru) Комбинации диклофенака и антагонистов h2-рецептора для лечения боли и воспаления